Which Telehealth Niche to Launch In (2026): Prices, Margins, Retention and Rules for 7 Verticals

Prices are entry prices from the Telehealth Match price database (179 DTC telehealth brands, mostly checked September–October 2026). It's our sister comparison site, and these are its own data. Generic cost-of-goods figures are Cost Plus Drugs retail prices pulled October 18, 2026. Neither is a full census of the market.

The seven verticals at a glance

Cost Plus prices are drug only, plus a $5 dispensing fee and shipping (Cost Plus Drugs). They're a public floor, not your pharmacy's wholesale cost. Brand prices aren't like-for-like: some include a membership, and many entry prices need a 6- or 12-month prepay.

GLP-1 weight loss

The opportunity: the biggest demand and the highest prices. Compounded injectable semaglutide had a median entry price of $150 a month across 73 brands (range $49–$400); tirzepatide $199 across 71. Branded prices now come from manufacturer self-pay programs. NovoCare lists the Wegovy pill at $149–$299 a month by dose and Wegovy pens at $349 after an introductory offer (NovoCare). Most telehealth brands pass those through and charge a membership, which is why branded offers in the database split into a $199–$600 group (self-pay plus membership) and a $650–$1,498 group (list price at the patient's pharmacy).

The catch: compounded GLP-1s are now tightly restricted and actively enforced (see 503A vs 503B). Drop-off is fast: in a study of 125,474 adults, 64.8% of patients without type 2 diabetes stopped within a year (JAMA Network Open, 2025). The FTC's case against NextMed shows that advertising a price that leaves out the drug, labs or consult is treated as deceptive (FTC).

TRT and men's health

The opportunity: a median $100 a month for testosterone across 27 brands, enclomiphene $107. Every brand sells or requires labs, which add revenue.

The catch: testosterone is Schedule III (21 CFR 1308.13), so new telemedicine prescriptions depend on the DEA flexibilities that run through December 31, 2026 (see our structure guide). Retention is weak: one study of 121,852 men found only 8.2% still on testosterone cypionate at 12 months (Androgens, 2022). Enclomiphene isn't FDA-approved, and FDA proposed in 2022 that it not be added to the compounding bulks list (FDA), so treat it as a grey zone. FDA's 2025 relabel removed the boxed-warning language on cardiovascular risk but kept the limitation on "age-related" low testosterone (FDA). Keep claims to diagnosed hypogonadism.

Menopause and HRT

The opportunity: FDA began removing the boxed warnings on cardiovascular disease, breast cancer and dementia from menopausal hormone therapy in November 2025, and approved the first relabeled products in February 2026 (FDA). Medication is cheap (estradiol 1 mg is $1.77 for 30 at Cost Plus), and estrogen offers had a median entry price of $74. Hims expects menopause to help push its Hers brand toward $1 billion of revenue in 2026.

The catch: compounded "bioidentical" hormones aren't FDA-approved. The Menopause Society says "patient preference alone should not be used to justify" them and calls saliva-based dosing "unreliable" (Menopause Society). Lead with FDA-approved generics, and don't claim "FDA says HRT is safe": endometrial cancer warnings and other label risks remain.

Hair loss

The opportunity: finasteride 1 mg costs $0.82 for 30 tablets at Cost Plus, async photo intake is the norm, and patients take it long-term. Topical minoxidil is over the counter, so it can be advertised without prescription-drug ad rules.

The catch: prices are low (a median of $20 for finasteride, with big brands at $16–$29), so margin comes from compounded combos and bundles (median $50). FDA issued an alert in April 2025 on compounded topical finasteride, citing reports of persistent sexual and psychiatric side effects and naming telehealth marketers (FDA). Don't call topical finasteride FDA-approved or side-effect-free.

ED

The opportunity: generics cost pennies (tadalafil 5 mg $0.98 for 30), and a 2023 study found 93% of DTC ED platforms prescribe from an online intake alone (Sexual Medicine, 2023). Compounded chews and combos command a premium (median $60).

The catch: heavy competition and low prices (generics at a median $39), and about half of men stop PDE5 inhibitors within a year (Andrology, 2016). FDA warned BlueChew in September 2025 over claims such as "same active as Viagra" for compounded products (FDA). ED is also a classic auto-renewing subscription, the area the FTC's 2026 case against Hims targets (FTC).

Rx skincare

The opportunity: tretinoin costs $9.17 for 20 g at Cost Plus, photo-based async care works, and custom formulas let a brand differentiate. Premium anti-aging lines are priced far above acne.

The catch: a low median price ($30) and big incumbents (Curology, Hims, Musely). Custom compounded creams aren't FDA-approved, and anti-aging use of tretinoin is off-label. Isotretinoin stays under the iPLEDGE program even after its changes take effect November 15, 2026 (FDA), so it can't be run fully async.

Longevity

The opportunity: NAD+ injections (median $145, 52 brands) and sermorelin ($149, 43 brands) are popular add-ons, mostly sold by GLP-1 brands. Rapamycin, metformin and low-dose naltrexone are cheap to supply.

The catch: the evidence. The PEARL trial of weekly rapamycin missed its primary endpoint (Aging, 2025), and a meta-analysis of NMN trials found no significant metabolic effect. The FTC requires competent and reliable scientific evidence, generally randomized human trials, for health claims (FTC), so "reverses aging" is very hard to support. FDA has warned compounders against food-grade NAD+ in injections (FDA). Peptide status is in our peptide guide.

Full launch guides by vertical

• GLP-1 weight loss
• TRT and men's health
• Menopause and HRT
• Hair loss
• ED
• Rx skincare
• Longevity

How to choose

1. Start from your audience. Creators and brands with a women's audience fit menopause, skin and weight. Men's fitness audiences fit hair, ED and, carefully, TRT.
2. Check the margin with real quotes. Put your price, pharmacy and clinician costs into the profit calculator. In cheap-drug verticals, pharmacy dispensing and shipping fees, not the drug, set your cost.
3. Plan for retention. In verticals where half of patients stop within a year, your acquisition cost has to pay back within a few months.
4. Price the regulatory risk. Controlled substances, compounded copies of approved drugs and unsupported claims are where brands get hurt.
5. Bundle adjacent needs. Hims raised revenue per subscriber from $54 to $92 largely through multi-condition plans (our Hims teardown).

---